Clinical Trial Update: Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Deferasirox in transfusion-dependent beta-thalassemia patients with myocardial iron overload (cardiac MRI T2* < 20 ms) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transfusion-dependent Beta-thalassemia

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Beta Thalassemia Transfusion Dependent | Phase 2 | Status: COMPLETED